MRK | Weekly | Haru Insights

The $5.7 billion in one-time charges from the Terns Pharmaceuticals and Cidara acquisitions, driving a $0.13 EPS miss and a dramatic revision of full-year non-GAAP EPS guidance to $2.66–$2.76, marks the single most significant financial event of the week.
The approval of Keytruda in combination with enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer in Canada, supported by strong Phase 3 data, represents a pivotal clinical and commercial milestone reinforcing Keytruda’s expanding label and market dominance.

Keytruda’s relentless revenue momentum—$8.4 billion in Q2 alone—solidifies its status as a durable, high-margin cornerstone with unparalleled commercial reach across multiple cancer types and global markets.
The Canadian approval of Keytruda’s combination therapy in bladder cancer, backed by superior survival outcomes, confirms Merck’s ability to rapidly translate clinical superiority into real-world market leadership and guideline adoption.
The aggressive pursuit of pipeline diversification through high-impact acquisitions like Terns and the planned purchase of Bio-Techne signals a bold, forward-looking strategy to transition beyond Keytruda dependency and build long-term innovation infrastructure.
Breakthrough innovations like LIPFENDRA, the first oral PCSK9 inhibitor, and Winrevair’s 75% YoY sales surge highlight Merck’s ability to deliver transformative therapeutics in non-oncology areas, proving its R&D engine remains potent and adaptable.
The market’s 25.5% year-to-date stock surge, despite earnings volatility, reflects strong investor belief in Merck’s strategic pivot and resilience—evidence that the market is pricing in a structural transformation, not just a short-term rebound.

Merck & Co., Inc. (MRK)[Tv]